Skip to main content
SpringerLink
Log in

Taxol (paclitaxel): a novel anti-microtubule agent with remarkable anti-neoplastic activity

  • Reviews
  • Published:
International Journal of Clinical and Laboratory Research

Summary

Taxol (paclitaxel), an anti-microtubule agent extracted from the needles and bark of the Pacific yew treeTaxus brevifolia, has shown a remarkable anti-neoplastic effect in human cancer in phase I studies and early phase II and III trials thus far conducted. This has been reported primarily in advanced ovarian and breast cancer, although significant activity has also been documented in small-cell and non-small-cell lung cancer, head and neck cancers, and with lower activity in metastatic melanoma. The clinical utilization of Taxol had been previously somewhat restricted by its limited availability, a limitation that has recently been overcome by combined efforts of pharmaceutical, agricultural, and governmental agencies. In this review we shall address the pre-clinical data which have led to the use of Taxol in man, the main clinical results thus far obtained, the toxicities associated with its use, current ongoing trials and future clinical directions of this promising agent.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Wani MC, Taylor HL, Wall ME, et al, Plant antitumor agents. VI. The isolation and structure of Taxol, a novel antileukemic and antitumor agent fromTaxus brevifolia, J Am Chem Soc 93:2325, 1991

    Article  Google Scholar 

  2. Rowinsky EK, Cavenave LA, Donehower RC, Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst 82:1247, 1990

    Article  PubMed  CAS  Google Scholar 

  3. Schiff PB, Fant J, Horwitz SB, Promotion of microtubule assembly in vitro by Taxol. Nature 277:665, 1979

    Article  PubMed  CAS  Google Scholar 

  4. Kumar N, Taxol-induced polymerization of purified tubulin. Mechanism of action. J Biol Chem 256:10435, 1981

    PubMed  CAS  Google Scholar 

  5. Manfredi JJ, Horwitz SB, Taxol: an antimitotic agent with a new mechanism of action. Pharmacol Ther 25:83, 1984

    Article  PubMed  CAS  Google Scholar 

  6. Rao S, Horwitz SB, Ringel I, Direct photoaffinity labeling of tubulin with Taxol. J Natl Cancer Inst 84:785, 1992

    Article  PubMed  CAS  Google Scholar 

  7. Parness J, Horwitz SB, Taxol binds to polymerized tubulin in vitro. J Cell Biol 91:479, 1981

    Article  PubMed  CAS  Google Scholar 

  8. Dustin P, Microtubules. Sci Am 243:66, 1980

    Article  PubMed  CAS  Google Scholar 

  9. Roberts JR, Rowinsky EK, Donehower RC, et al, Demonstration of the cell cycle positions for Taxol-induced “asters” and “bundles” by sequential measurements of tubulin immunofluorescence, DNA content, and autoradiographic labeling of Taxolsensitive and resistant cells. J Histochem Cytochem 37:1659, 1989

    PubMed  CAS  Google Scholar 

  10. Taxol clinical brochure. National Cancer Institute, Bethesda, 1983

  11. Choy H, Rodriguez FF, Koester S, et al, Investigation of Taxol as a potential radiation sensitizer. Cancer 71:3774, 1993

    Article  PubMed  CAS  Google Scholar 

  12. Investigational Drug Branch, National Cancer Institute, Taxol (NSC 125973) clinical brochure. National Cancer Institute, Bethesda, 1990

    Google Scholar 

  13. Lorenz W, Reimann HJ, Schmal A, et al, Histamine release in dogs by Cremophor EL and its derivatives: oxyethylated oleic acid is the most effective constituent. Agents Actions 7:63, 1977

    Article  PubMed  CAS  Google Scholar 

  14. Roth B, Yeap B, Wilding G, et al, Taxol (NSC 125973) in advanced, hormone-refractory prostate cancer: an ECOG phase II trial. Proc Am Soc Clin Oncol 11:196, 1992

    Google Scholar 

  15. Sarosy G, Kohn E, Stone DA, et al, Phase I study of Taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer. J Clin Oncol 10:1165, 1992

    PubMed  CAS  Google Scholar 

  16. Levin L, Hryniuk W, The application of dose intensity to problems in chemotherapy of ovarian and endometrial cancer. Semin Oncol 5:756, 1987

    CAS  Google Scholar 

  17. McGuire WP, Rowinsky EK, Rosenhein NB, et al, Taxol: a unique antineoplastic agent with significant antitumor activity in advanced ovarian epithelial neoplasms. Ann Intern Med 111:273, 1989

    PubMed  CAS  Google Scholar 

  18. Einzig AI, Wiernik P, Sasloff J, et al, Phase II study and long-term follow-up of patients treated with Taxol for advanced ovarian adenocarcinoma. J Clin Oncol 10:1748, 1992

    PubMed  CAS  Google Scholar 

  19. Thipgen T, Blessing J, Ball H, et al, Phase II trial of Taxol as second-line therapy for ovarian carcinoma: a Gynecologic Oncology Group study. Proc Am Soc Clin Oncol 9:604, 1990

    Google Scholar 

  20. Sarosy G, Kohn E, Link C, et al, Taxol dose intensification in patients with recurrent ovarian cancer. Proc Am Soc Clin Oncol 11:226, 1992

    Google Scholar 

  21. Einzig AI, Gorowski E, Sasloff J, et al, Phase II trial of Taxol in patients with metastatic renal cell carcinoma. Cancer Invest 9:133, 1991

    PubMed  CAS  Google Scholar 

  22. Holmes FA, Frye D, Theriault RS, et al, Phase II trial of Taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83:1797, 1991

    Article  PubMed  CAS  Google Scholar 

  23. Reichman BS, Seidman AD. Crown JPA. et al, Taxol and recombinant granulocyte colony stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol (in press)

  24. Einzig AL, Wiernik PH, Lipsitz S, et al, Phase II trial of Taxol in patients with adenocarcinoma of the upper gastrointestinal tract (UGIT). Proc Am Soc Clin Oncol 12:194, 1993

    Google Scholar 

  25. Forastiere AA, Neuberg D, Taylor IV SG, et al, Phase II evaluation of Taxol in advanced head and neck cancer: an Eastern Cooperative Oncology Group trial. Proc. Am Soc Clin Oncol 12:277, 1993

    Google Scholar 

  26. Wilson WH, Berg S, Kang Y-K, et al, Phase I/II study of taxol 96-hour infusion in refractory lymphoma and breast cancer: pharmacodynamics and analysis of multidrug resistance (mdr-1). Proc Am Soc Clin Oncol 12:134, 1993

    Google Scholar 

  27. Einzig AI, Hochster HH, Wiernik PH, et al, Phase II trial of Taxol in patients with metastatic melanoma. Invest New Drugs 9:54, 1991

    Article  Google Scholar 

  28. Legha SS, Ring S, Papadopoulos N, A phase II trial of Taxol in metastatic melanoma. Cancer 65:2478, 1990

    Article  PubMed  CAS  Google Scholar 

  29. Chang AY, Kim K, Glick J, et al, Phase II study of Taxol, Merbarone, and Piroxantrone in stage IV non-small-cell lung cancer: the Eastern Cooperative Oncology Group results. J Natl Cancer Inst 85:388, 1993

    Article  PubMed  CAS  Google Scholar 

  30. Murphy WK, Fossella FV, Winn RJ, et al, Phase II study of Taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst 85:384, 1993

    Article  PubMed  CAS  Google Scholar 

  31. Brown T, Tangen C, Fleming T, et al, A phase II trial of Taxol and granulocyte colony stimulating factor (G-CSF) in patients with adenocarcinoma of the pancreas. Proc Am Soc Clin Oncol 12:200, 1993

    Google Scholar 

  32. Ettinger DS, Finkelstein DM, Sarma R, et al, Phase II study of Taxol in patients with extensive-stage small cell lung cancer (SCLC): an Eastern Cooperative Oncology Group Study. Proc Am Soc Clin Oncol 12:1095, 1993

    Google Scholar 

  33. Swenerton K, Eisenhauer E, Bokkel Huinink W ten, et al, Taxol in relapsed ovarian cancer: high vs low dose and short vs long infusion. Proc Am Soc Clin Oncol 12:256, 1993

    Google Scholar 

  34. Nabholtz JM, Gelmon K, Bontenbal M, et al, Randomized trial of two doses of Taxol in metastatic breast cancer: an interim analysis. Proc Am Soc Clin Oncol 12:60, 1993

    Google Scholar 

  35. Seidman AD, Crown JPA, Reichman BS, et al, Lack of clinical cross-resistance of Taxol with anthracycline in the treatment of metastatic breast cancer. Proc Am Soc Clin Oncol 12:63, 1993

    Google Scholar 

  36. Seidman AD, McCarthy J, Anthony V, et al, Pain and quality of life assessment in patients receiving Taxol and recombinant human granulocyte colony stimulating factor for metastatic breast cancer. Proceedings of the 2nd National Cancer Institute Workshop on Taxol and Taxus September 23–24, 1992

  37. Holmes FA, Valero V, Theriault RL, et al, Phase II trial of Taxol in metastatic breast cancer refractory to multiple prior treatments. Proc Am Soc Clin Oncol 12:94, 1993

    Google Scholar 

  38. Rowinsky EK, Gilbert MR, McGuire WP, et al, Sequences of Taxol and cisplatin: a phase I and pharmacologic study. J Clin Oncol 9:1692, 1991

    PubMed  CAS  Google Scholar 

  39. Forastiere AA, Rowinsky E, Chaudry V, et al, Phase I trial of Taxol (T) and cisplatin (C)+G-CSF in solid tumors. Proc Am Soc Clin Oncol 289:1992

  40. Holmes FA, Frye D, Valero V, et al, Phase I study of Taxol (T) and doxorubicin (D) with G-CSF in patients without prior chemotherapy (CT) for metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 11:60, 1992

    Google Scholar 

  41. Fisherman J, McCabe M, Hillig M, et al, Phase I study of Taxol and doxorubicin (DOX) with G-CSF in previously untreated metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 11:57, 1992

    Google Scholar 

  42. Pestalozzi BC, Sotos GA, Choyke PL, et al, Typhlitis resulting from treatment with Taxol and doxorubicin in patients with metastatic breast cancer. Cancer 71:1797, 1993

    Article  PubMed  CAS  Google Scholar 

  43. Kennedy MJ, Donchower RC, Sartorius SE, et al, Sequences of Taxol and cyclophosphamide: a phase I and pharmacologic study in doxorubicin resistant metastatic breast cancer. Proc Am Soc Clin Oncol 12:165, 1993

    Google Scholar 

  44. Kohn E, Reed E, Link C, et al, A pilot study of Taxol, cisplatin, cyclophosphamide, and G-CSF in newly diagnosed stage III/IV ovarian cancer patients. Proc Am Soc Clin Oncol 12:257, 1993

    Google Scholar 

  45. McGuire WP, Hoskins WJ, Brady MF, et al, A phase III trial comparing cisplatin/cytoxan (PC) and cisplatin/taxol (PT) in advanced ovarian cancer (AOC), Proc Am Soc Clin Oncol 12:255, 1993

    Google Scholar 

  46. Hudis C, Lebwohl D, Crown J, et al, Feasibility of dose-intensive cyclophosphamide with G-CSF after doxorubicin in women with high risk stage II/III resectable breast cancer. Proc Am Soc Clin Oncol 11:55, 1992

    Google Scholar 

  47. Weiss R, Donehower RC, Cates AE, et al, Hypersensitivity reactions from Taxol. J Clin Oncol 8:1263, 1990

    PubMed  CAS  Google Scholar 

  48. National Cancer Institute Clinical Brochure: Taxol (NSC 125973). Division of Cancer Treatment, National Cancer Institute, Bethesda, 1991

    Google Scholar 

  49. Peereboom DM, Donehower RC, Eisenhauer A, et al, Successful re-treatment with Taxol after major hypersensitivity reactions. J Clin Oncol 11:885, 1993

    PubMed  CAS  Google Scholar 

  50. Brown T, Havlin K, Weiss G, Cagnola J, Koeller J, Kuhn J, Rizzo J, Craig J, Phillips J, Von-Hoff D, A phase I trial of Taxol given by a 6-hour intravenous infusion. J Clin Oncol 9:1261, 1991

    PubMed  CAS  Google Scholar 

  51. Roberts RL, Nath J, Friedman MM, Gallin JI, Effects of Taxol on human neutrophils. J Immunol 129:2134, 1982

    PubMed  CAS  Google Scholar 

  52. Lipton RB, Apfel SC, Dutcher JP, et al, Taxol produces a predominantly sensory neuropathy. Neurology 39:368, 1989

    PubMed  CAS  Google Scholar 

  53. Masurovsky EB, Peterson ER, Crain SM, et al, Morphological alterations in dorsal root ganglion neurons and supporting cells of organotypic mouse spinal cord-ganglion cultures exposed to Taxol. Neuroscience 10:491, 1983

    Article  PubMed  CAS  Google Scholar 

  54. Letourneau PC, Shattuck TA, Ressler AH, et al, Branching of sensory and sympathetic neurites in vitro is inhibited by treatment with Taxol. J Neurosci 6:1912, 1986

    PubMed  CAS  Google Scholar 

  55. Rowinsky EK, McGuire WP, Guarnieri T, et al, Cardiac disturbances during the administration of Taxol. J Clin Oncol 9:1704, 1991

    PubMed  CAS  Google Scholar 

  56. Rowinsky EK, Burke PJ, Karp JE, et al, Phase I and pharmacodynamic study of Taxol in refractory acute leukemias. Cancer Res 49:4640, 1989

    PubMed  CAS  Google Scholar 

  57. Hruban RH, Yardley JH, Donehower RC, et al, Taxol toxicity: epithelial necrosis in the gastrointestinal tract associated with polymerized microtubule accumulation and mitotic arrest. Cancer 63:1944, 1989

    Article  PubMed  CAS  Google Scholar 

  58. Markman MM, Rowinsky E, Hakes T, et al, Phase I trial of intraperitoneal Taxol: a Gynecologic Oncology Group study. J Clin Oncol 9:1485, 1992

    Google Scholar 

  59. Francis P, Rowinsky E, Hakes T, et al, Phase I trial of weekly intraperitoneal (IP) Taxol in patients with residual ovarian carcinoma. Proc Am Soc Clin Oncol 12:257, 1993

    Google Scholar 

  60. Ringel I, Horwitz SB, Studies with RP 56976 (Taxotere): a semisynthetic analogue of Taxol. J Natl Cancer Inst 83:288, 1991

    Article  PubMed  CAS  Google Scholar 

  61. Bissery M-C, Guenard D, Gueritte-Voegelein F, Lavelle F, Experimental antitumor activity of Taxotere (RP 56976, NSC 628503), a Taxol analogue. Cancer Res 51:4845, 1991

    PubMed  CAS  Google Scholar 

  62. Aapro M, Braakhuis B, Dietel M, et al, Superior activity of Taxotere (Ter) over Taxol (Tol) in vitro. Proc Am Assoc Cancer Res 33:516, 1992

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dipartimento di Scienze Biomediche e Oncologia Umana, Sezione Clinica, Via Genova 3, I-10126, Turin, Italy

    Robin Foa

  2. Breast and Gynecological Cancer Medicine Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 10021, New York, NY, USA

    Larry Norton & Andrew D. Seidman

Authors
  1. Robin Foa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Larry Norton
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Andrew D. Seidman
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Foa, R., Norton, L. & Seidman, A.D. Taxol (paclitaxel): a novel anti-microtubule agent with remarkable anti-neoplastic activity. Int J Clin Lab Res 24, 6–14 (1994). https://doi.org/10.1007/BF02592403

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02592403

Key words

Search

Navigation